Topics:
Breast Cancer • Medical Oncology
How do you decide about neoadjuvant chemotherapy in a women with both IDC and DCIS on biopsy when the tumor is ill defined on imaging?
NCCN recommendations seem to mention these patients as not candidates for preoperative systemic therapy if the invasive carcinoma extension cannot be delineated from extensive DCIS.
Answer from: Medical Oncologist at Academic Institution
In the clinical scenario of a palpable tumor and biopsy reflecting a mix of pre-invasive disease (DCIS) and proliferative cancer, the value of neoadjuvant chemotherapy is debatable. The optimal goal of NAC is to ameliorate long term outcome, that was documented with pCR, these quite low in original ...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
I would say the answer depends on the subtype of Invasive breast cancer. I would be fine considering Neo-adjuvant systemic therapy in the setting of TNBC and Her 2 Positive breast cancer as I would not be doing any harm even if invasive component is really small like only about 5 mm
I would...